The tests were conducted from May to September in close collaboration with leading scientists and government regulators. The study involved 66 patients with severe pneumonia caused by COVID-19.
Patients were stationed at 9 clinical bases in different regions of Ukraine (in Kyiv, Bila Tserkva, Lviv, Odesa, Vinnytsia, Ternopil, Ivano-Frankivsk and Lutsk).
During Bioven’s research, Ukrainian and international experts noted that it improves immunity, prevents inflammation in human blood, reduces the severity of cytokine storms, and reduces markers of inflammation to normal values.
The use of the drug is highly safe. If you follow the rules of antiseptics and dosing regimen, side effects do not develop.
The inclusion of Bioven in the therapy can accelerate recovery and minimize the likelihood of life-threatening consequences:
– 1.5 times faster to improve the patient’s condition
– reduce mortality by 4 times
– cut in half the period of normalization of the immune cells’ number
– significantly reduces the time spent on ventilators
Currently, similar drugs are in the process of summarizing the results of clinical trials in several countries. Thus, thanks to the experience of Biopharma, Ukrainians have gained access to treatment in accordance with global trends.
Kostiantyn Efymenko, Managing Partner of the pharmaceutical company Biopharma
We decided to start clinical trials based on the suggestions of Ukrainian medical experts who traditionally use our drug to treat viral and bacterial pneumonias. Now we see that the assumption of Ukrainian experts turned out to be correct. We hope that based on the results of research, the drug will soon be included in the treatment protocol COVID-19.
Maksym Stepanov, Minister of Health of Ukraine
Clinical trials of the Ukrainian drug Bioven have already ended, and there are relevant reports. The results are comforting. The manufacturer has conducted clinical trials, confirmed the effectiveness of this drug and we will soon include it in our treatment protocol for coronavirus.